CellaVision has received its first order for the analyzer, CellaVision ® DM96 Vet System which was launched in the North American Veterinary market in the early part of 2012. The order was placed by one of North America's largest veterinary reference laboratory chains with operations at many locations.
"We are delighted to see the first order from the veterinary market. With this order we have equipped the first of many reference laboratories with the CellaVision ® DM96 Vet System. This is an important first step which will help make the Veterinary lab market aware of the value of CellaVision's solutions. The order is of strategic value for us because the product provides us with additional growth opportunities in our core market segment, hematology, "says Yvonne Mårtensson, CEO of CellaVision.
The CellaVision DM96 Vet System replaces the manual microscope for performing blood differentials in veterinary laboratories, the same way it does in the human market. The product is a customized version of CellaVision's existing instruments for human blood with the capacity to analyze the blood of companion animals, e.g., cats and dogs. The initial target group is the over one hundred large veterinary laboratories in the U.S. and Canada, where the volume of samples is high and the need for efficient analysis method is great. A key driver in this market is the utilization of CellaVision® Remote Review Software which will allow a lab's differentials to be performed from any external location. In Europe and other geographic markets, companion animal blood analyses are often not performed in the reference laboratories but rather are done in smaller veterinary laboratories or human hospital laboratories. CellaVision sells the product directly to the end customer.For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. Email: email@example.com About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2011 sales were SEK 155 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com